Mammalian target of rapamycin inhibition as therapy for hematologic malignancies (multiple letters)

Cancer

Volumn 101, Issue 6, 2004, Pages 1478-

  Cutler, Corey ^a   Antin, Joseph H ^a   Giles, Francis J ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOPHILIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; COMPLEX FORMATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; LETTER; NOMENCLATURE; PRIORITY JOURNAL;

HEMATOLOGIC NEOPLASMS; HUMANS; PROTEIN KINASES; SIROLIMUS;

EID: 4444258766     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20495     Document Type: Letter

References (0)